MedTrace Logo

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

NCT05307770 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-05-29

No results posted yet for this study

Summary

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

Conditions

  • Rapid Eye Movement Sleep Behavior Disorder
  • Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

Immediate Release Melatonin

5 mg orally every night at 9 pm for 4 weeks

DIETARY_SUPPLEMENT

Extended Release Melatonin

5 mg orally every night at 9 pm for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Emir Festic, MD, MS · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307770 on ClinicalTrials.gov